Cell & Gene Therapy

Pharma

Genentech starts phase 2 trial to optimize cell therapy delivery

Genentech has kicked off a phase 2a clinical trial to optimize subretinal surgical delivery of the eye disease cell therapy OpRegen.
Nick Paul Taylor Nov 28, 2022 10:20am
Podcast

'The Top Line': Fierce Biotech's Cell & Gene Therapy Forum

Nov 11, 2022 6:00am

Charles River cell therapy push powers on with latest expansion

Nov 8, 2022 9:45am

Vision loss cell therapy implant hits primary goals in phase 3

Nov 8, 2022 7:45am

SK bioscience unveils strategy aimed at global market expansion

Nov 3, 2022 10:30am

ReiThera opens €15M bio production after regulatory signoff

Nov 3, 2022 9:15am
More News

Sumitomo-Myovant, Astellas-Taysha, Genentech—Fierce Pharma Asia

Oct 28, 2022 9:15am

Zolgensma decline unrelated to gene therapy deaths: Novartis CEO

Oct 25, 2022 10:25am

VectorBuilder bags $57M to build out gene delivery capabilities

Oct 25, 2022 8:45am

J&J, Legend's CAR-T nets $55M sales before key readout

Oct 20, 2022 11:17am